scholarly journals Supernormal Flicker ERGs in Eyes With Central Retinal Vein Occlusion: Clinical Characteristics, Prognosis, and Effects of Anti-VEGF Agent

2018 ◽  
Vol 59 (15) ◽  
pp. 5854 ◽  
Author(s):  
Ryohei Miyata ◽  
Mineo Kondo ◽  
Kumiko Kato ◽  
Masahiko Sugimoto ◽  
Hisashi Matsubara ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Clinical Characteristics ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Christina L. Ryu ◽  
Adrian Elfersy ◽  
Uday Desai ◽  
Thomas Hessburg ◽  
Paul Edwards ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Significant Risk ◽  
Case Series ◽  
Neovascular Glaucoma ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Real-World Visual and Neovascularisation Outcomes from anti-VEGF in Central Retinal Vein Occlusion

2020 ◽  
Vol 28 (1) ◽  
pp. 70-76
Author(s):  
H. D. Jeffry Hogg ◽  
S. James Talks ◽  
Mark Pearce ◽  
Sandro Di Simplicio
Keyword(s):  
Retinal Vein Occlusion ◽  
Real World ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion

2017 ◽  
Vol Volume 11 ◽  
pp. 331-336 ◽  
Author(s):  
Kaveh Abri Aghdam ◽  
Lukas Reznicek ◽  
Mostafa Soltan Sanjari ◽  
Annemarie Klingenstein ◽  
Marcus Kernt ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

scholarly journals MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants

2019 ◽  
Vol 6 (3) ◽  
pp. 159-163
Author(s):  
Jasmine H. Francis ◽  
Eli L. Diamond ◽  
Ping Chi ◽  
Korey Jaben ◽  
David M. Hyman ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Elevated Serum ◽  
Rare Event ◽  
Case Series ◽  
Mek Inhibitor ◽  
Cancer Center ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Background: Central retinal vein occlusion (CRVO) is a visually threatening event that has rarely been observed in patients taking MEK1/2 inhibitors and that may necessitate permanent discontinuation of a potentially efficacious therapy. We investigated the clinical characteristics of CRVO in patients on mitogen-activated protein kinase kinase (MEK) inhibition to better understand their predisposing factors and clinical course. Case Series: This was a single-center, retrospective cohort study (between December 2006 and September 2018). Three of 546 patients enrolled in 46 prospective trials involving treatment with MEK inhibitors at Memorial Sloan Kettering Cancer Center were identified as having CRVO. Clinical examination and course, multimodal ophthalmic imaging, and serum laboratory results (including homocysteine levels and genetic variants of methylene tetrahydrofolate reductase [MTHFR]) were reviewed for the 3 affected patients. All 3 patients with MEK inhibitor-associated CRVO had elevated serum homocysteine and gene variants of MTHFR (1 homozygous for A1298C, 1 heterozygous for A1298C, and 1 homozygous for C677T). Following intravitreous injections of anti-VEGF and discontinuation of drug, all patients regained vision to their baseline. Discussion: MEK inhibitor-associated CRVO is a rare event which can exhibit visual recovery after drug cessation and intravitreous anti-VEGF injections. In this cohort, it was associated with hyperhomocysteinemia and genetic mutations in MTHFR, suggesting a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy.

Predictors of Short-Term Visual Outcome after Anti-VEGF Therapy of Macular Edema due to Central Retinal Vein Occlusion

2011 ◽  
Vol 52 (6) ◽  
pp. 3334 ◽  
Author(s):  
Ute E. K. Wolf-Schnurrbusch ◽  
Ramzi Ghanem ◽  
Simon P. Rothenbuehler ◽  
Volker Enzmann ◽  
Carsten Framme ◽  
...  
Keyword(s):  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Visual Outcome ◽  
Short Term ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Central Retinal Vein

Characteristics of Central Retinal Vein Occlusion in African Americans

2019 ◽  
Vol 4 (3) ◽  
pp. 186-191
Author(s):  
Sieh Yean Kiew ◽  
George N. Thomas ◽  
Akshay S. Thomas ◽  
Sharon Fekrat
Keyword(s):  
African American ◽  
African Americans ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
First Year ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Patient Reported ◽  
Treatment Naïve ◽  
Central Retinal Vein

Purpose: This article studies whether the characteristics and clinical course of African American patients with central retinal vein occlusion (CRVO) differ from other racial groups. Methods: This retrospective cohort study included consecutive patients diagnosed with CRVO at Duke Eye Center, Durham, North Carolina. Presenting characteristics, examination findings, treatment course, and functional and structural outcomes were compared based on patient-reported race. Results: A total of 479 patients with CRVO were included (64.7% white, 22.2% African American, 1.7% mixed race, and 11.4% other races). African American patients were older (68.1 vs 64.3 years, P = .049), more likely to be hypertensive ( P = .001) and diabetic ( P = .000), and had higher rates of open-angle glaucoma ( P < .000). Presenting visual acuity (VA) was worse in African Americans (logarithm of the minimum angle of resolution 1.25 vs 0.96, P = .010). There were no significant differences in the proportion of patients requiring panretinal photocoagulation, intravitreal antivascular endothelial growth factor (anti-VEGF), or intravitreal corticosteroid; however, analysis of treatment-naive individuals showed a higher number of anti-VEGF injections in the first year in African Americans. Final VA was not significantly different between groups, but African Americans had higher rates of neovascular sequelae (25.0% vs 11.8%, P = .019; odds ratio, 2.295, P = .088). Conclusions: African Americans with CRVO presented with more severe visual impairment and more systemic and ocular risk factors for CRVO. Treatment-naive African Americans had a greater treatment burden during the first year of follow-up.

scholarly journals Treatment Patterns and Clinical Outcomes for Central Retinal Vein Occlusion in the Antivascular Endothelial Growth Factor Era

2019 ◽  
Vol 4 (1) ◽  
pp. 13-21
Author(s):  
Jeannette Y. Stallworth ◽  
Akshay S. Thomas ◽  
Ryan Constantine ◽  
Sandra S. Stinnett ◽  
Sharon Fekrat
Keyword(s):  
Growth Factor ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Treatment Patterns ◽  
Vein Occlusion ◽  
Anti Vegf ◽  
Antivascular Endothelial Growth Factor ◽  
Endothelial Growth Factor ◽  
Central Retinal Vein

Purpose: This article describes treatment patterns and visual outcomes for central retinal vein occlusion (CRVO) in the antivascular endothelial growth factor (anti-VEGF) era. Methods: A retrospective cohort study of eyes diagnosed with CRVO between 2009 and 2016 was conducted. Treatment history and visual acuity (VA) measurements were abstracted from medical records and analyzed. Results: A total of 476 eyes of 476 patients (median age 67 years, median follow-up 25.4 months) were included. Optical coherence tomography was obtained in 93.9% and fluorescein angiography in 80% of cases on presentation. Mean VA at presentation and final visit was 20/60 and 20/94, respectively, for eyes with nonischemic CRVO, whereas that of ischemic cases remained worse than 20/800 at final follow-up. Intravitreal bevacizumab was the most common first treatment (42.2%). Intravitreal steroid was the first treatment in 3.6% and ultimately administered in 11.3% of eyes. In the first year, an average of 5.2 ± 3.6 and 2.2 ± 3.4 anti-VEGF injections were given in treatment-naive and nontreatment-naive eyes, respectively. Conclusions: In our real-world cohort, anti-VEGF injection burden and frequency are lower than in published clinical trials. Visual outcomes in both ischemic and nonischemic eyes with CRVO are poorer than expected and worse than those recorded in controlled trial settings.

Sign in / Sign up

Export Citation Format

Share Document